Clinical Scorecard: Beta-2 Agonists Tied to ASD Risk?
At a Glance
| Category | Detail |
|---|---|
| Condition | Autism Spectrum Disorder |
| Key Mechanisms | Prenatal exposure to beta-2-adrenergic agonists |
| Target Population | Pregnant individuals with asthma |
| Care Setting | Observational studies in high-income countries |
Key Highlights
- Prenatal exposure to beta-2-adrenergic agonists associated with ASD risk.
- Adjusted pooled effect estimate of 1.29 for ASD with prenatal exposure.
- Preconception exposure associated with an adjusted pooled effect estimate of 1.34.
- Mixed evidence for associations with other neurodevelopmental outcomes.
- Concerns about confounding by indication or asthma severity.
Guideline-Based Recommendations
Diagnosis
- Consider prenatal exposure to beta-2-adrenergic agonists in ASD assessments.
Management
- Continue asthma medication during pregnancy as per Global Initiative for Asthma guidance.
Monitoring & Follow-up
- Monitor for neurodevelopmental outcomes in offspring of mothers exposed to beta-2-adrenergic agonists.
Risks
- Potential confounding factors include maternal asthma severity and treatment indication.
Patient & Prescribing Data
Pregnant individuals with asthma requiring beta-2-adrenergic agonists.
Evidence suggests caution in interpreting associations with ASD due to confounding factors.
Clinical Best Practices
- Assess maternal asthma management during pregnancy.
- Evaluate the necessity of beta-2-adrenergic agonists on a case-by-case basis.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
